Trial Profile

Efficacy of low-dose erlotinib as maintenance therapy in patients of lung adenocarcinoma with EGFR mutation.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 Jul 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary)
Indications Lung cancer
Focus Therapeutic Use

Most Recent Events

09 Jul 2013 Planned end date changed from 1 Apr 2015 to 1 Apr 2020 as reported by University Hospital Medical Information Network - Japan record.
09 Jul 2013 Additional lead trial centres added as reported by University Hospital Medical Information Network - Japan record.
25 Apr 2011 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com